$RANI News

Rani Therapeutics Prices ~$20M Offering Of 12.48M Common Shares At $1.07/Share

Rani Therapeutics Hldgs Q1 EPS $(0.04), Inline, Sales $1.708M Beat $500.000K Estimate

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Canaccord Genuity Maintains Buy on Rani Therapeutics Hldgs, Lowers Price Target to $5

Companies Like Rani Therapeutics Holdings (NASDAQ:RANI) Are In A Position To Invest In Growth

HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

Rani Therapeutics Q4 Earnings Call Highlights

RANI THERAPEUTICS HOLDINGS-A (NASDAQ:RANI) Posts Q4 Revenue Miss Amid $1 Billion Chugai Partnership and $60M Financing

Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Hldgs Q4 EPS $(0.07) Misses $(0.06) Estimate, Sales $1.461M Miss $5.000M Estimate

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Retail investors account for 65% of Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) ownership, while private equity firms account for 17%

HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $11 Price Target

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Rani Therapeutics Initiated Phase 1 Trial of RT-114, an Orally Administered Ranipill Capsule Containing GLP-1/GLP-2 Dual Agonist, PG-102, for Obesity

Rani Therapeutics to Participate in the Evercore Healthcare Conference

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Hldgs Q3 EPS $(0.12) Beats $(0.15) Estimate